Research and Markets: Anacor's AN2728 (Atopic Dermatitis) - Forecast and Market Analysis to 2022

DUBLIN--()--Research and Markets ( has announced the addition of the "AN2728 (Atopic Dermatitis) - Forecast and Market Analysis to 2022" report to their offering.

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

Anacor is developing AN2728, a boron-containing small molecule for the potential treatment of atopic dermatitis. AN2728 inhibits phosphodiesterase 4 (PDE4) and reduces the production of TNF-a, a precursor involved in the immune response and subsequent inflammatory process seen in atopic dermatitis.


- Overview of Atopic Dermatitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on AN2728 including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for AN2728 for the top nine countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

4 Disease Management

4.1 Diagnosis

4.2 Treatment Overview

5 Competitive Assessment

5.1 Overview

5.2 Strategic Competitor Assessment

6 Opportunity and Unmet Need

6.1 Overview

6.2 Unmet Needs

6.2.1 A Systemic Drug for Severe Recalcitrant Patients

6.2.2 Tests that Stratify Patients and Allow for a Tailored Treatment Approach

6.2.3 A Drug that Effectively Controls Patients' Pruritus

6.2.4 Further Research into the Pathophysiology of Atopic Dermatitis

6.2.5 A Drug that Induces Disease Remission

6.2.6 Improved Quality of Life for Both Patients and their Carers

6.3 Unmet Needs Gap Analysis

6.4 Opportunities

6.4.1 Increase Treatment Armamentarium for Severe Recalcitrant Patients

6.4.2 Predictive Tests for Patient Stratification

6.4.3 More Therapeutic Options that Address Patients' Pruritus

7 Pipeline Assessment

8 AN2728

9 Appendix

For more information visit


Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals